Marc Bjurlin, DO, clinical assistant professor, department of urology, New York University (NYU) Langone Medical Center, discusses predictive models for prostate cancer risk.
One of the controversies in prostate cancer is which men require a prostate biopsy and of those men, which have a risk of having clinically significant cancer that warrants treatment, explained Bjurlin.
Bjurlin’s team built predictive models that can determine the likelihood of having cancer and of having high-risk disease. They did this using several different clinical parameters, including a multiparametric MRI of the prostate. This is used in conjunction with PSA and family history to determine if patients should get a biopsy and their likelihood of having clinically significant prostate cancer.